With More 2024 FDA Filings Planned, Novartis Drug Starts Showing Blockbuster Potential
Novartis drug iptacopan, which won its first FDA approval in early December in a rare blood disorder, has met the main goal of a pivotal test in an ultra-rare kidney disease. The small molecule’s potential to address many diseases has stirred up blockbuster expectations.
San Diego United States Shreeram Aradhye American Society Of Hematology Term Data Continue Support Iptacopan
Source: medcitynews.com